Initial Experience of Radiofrequency Ablation of Renal Tumor.
10.4111/kju.2006.47.3.244
- Author:
June HEO
1
;
Sung Kuk YUN
;
Gyung Tak SUNG
Author Information
1. Department of Urology, Diagnostic Radiology, Dong-A University School of Medicine, Busan, Korea. sunggt@daunet.donga.ac.kr
- Publication Type:Original Article
- Keywords:
Radiofrequency ablation;
Nephrons;
Laparoscopy
- MeSH:
Aged;
Catheter Ablation*;
Creatinine;
Follow-Up Studies;
Hematoma;
Hematuria;
Humans;
Kidney;
Laparoscopy;
Neoplasm, Residual;
Nephrons;
Physical Examination;
Tomography, X-Ray Computed;
Ultrasonography
- From:Korean Journal of Urology
2006;47(3):244-251
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We wanted to report the our early experience with performing nephron-sparing radiofrequency ablation (RFA) of renal tumor. MATERIALS AND METHODS: Three percutaneous RFAs were performed under combined computed tomography (CT) and ultrasonogram guided, and two intraoperative ultrasonograpy-guided laparoscopic RFAs were performed since June 2004. The treatment indications were localized, small (<4cm), solid renal masses in elderly patients and also the same type masses in the patients with comorbid conditions. The follow-up studies included physical examination, CBC, serum creatinine, urine analysis and kidney CT, and these were performed at day 1, 1 week, 1 month, 3 months, 6 months and 1 year after ablation, and then semi-annually thereafter. The mean follow-up duration was 8.8 months (range: 5-12 months). RESULTS: All five patients underwent successful RFA without any serious events. One patient had a mild perinephric hematoma and another patients had mild gross hematuria postoperatively. With a mean follow-up of 8.8 months, none of the patients showed any residual tumor on follow-up contrast-enhanced CT after the final tumor ablation. Complete tumor ablation was achieved after a single treatment session in 80% of the patients and in 20% of patients after the subsequent ablation sessions. CONCLUSIONS: Percutaneous or laparoscopic RFA is a promising nephron-sparing treatment for selected patients with small renal mass. Contrast-enhanced CT performed immediately after ablation is a reliable method to exclude residual viable tumor. The ultimate role for this modality will continue to evolve and this warrants further studies.
